×
ADVERTISEMENT

AUGUST 2, 2018

High Costs Lead Cancer Patients to Abandon or Delay Therapy



By Thomas Rosenthal


DENVER—Many patients are abandoning or delaying initiation of their oral oncolytic therapies because of the high cost of the medication, according to the results of a survey of pharmacy staff and administrators presented at the 2018 annual meeting of the Hematology/Oncology Pharmacy Association (poster TR165). 

More than a third of survey respondents reported that they had patients who had abandoned therapy due to high cost. Most respondents reported that they had